XRTX
Income statement / Annual
Last year (2025), XORTX Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, XORTX Therapeutics Inc's net income was -$2.66 M.
See XORTX Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$114.08 K
|
$111.64 K
|
$141.96 K
|
$74.61 K
|
$18.02 K
|
$20.44 K
|
$19.90 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$114.08 K
|
-$111.64 K
|
-$141.96 K
|
-$74.61 K
|
-$18.02 K
|
-$20.44 K
|
-$19.90 K
|
-$19.32 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$574.94 K
|
$175.00 K
|
$2.41 M
|
$9.16 M
|
$853.12 K
|
$277.46 K
|
$39.90 K
|
$342.25 K
|
$66.37 K
|
$0.00
|
| General & Administrative Expenses |
$1.83 M
|
$2.28 M
|
$2.23 M
|
$2.29 M
|
$1.58 M
|
$1.10 M
|
$506.17 K
|
$795.65 K
|
$380.92 K
|
$389.32 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$983.59 K
|
$461.18 K
|
-$473.61 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.83 M
|
$3.63 M
|
$2.39 M
|
$3.28 M
|
$2.05 M
|
$624.49 K
|
$506.17 K
|
$795.65 K
|
$380.92 K
|
$389.32 K
|
| Other Expenses |
$792.33 K
|
$1.65 M
|
$1.40 M
|
$1.13 M
|
$3.69 K
|
$180.30 K
|
$0.00
|
$19.32 K
|
-$20.18 K
|
$0.00
|
| Operating Expenses |
$3.20 M
|
$3.81 M
|
$4.81 M
|
$12.43 M
|
$2.90 M
|
$1.08 M
|
$546.07 K
|
$1.16 M
|
$427.11 K
|
$389.32 K
|
| Cost And Expenses |
$3.31 M
|
$3.92 M
|
$6.16 M
|
$12.43 M
|
$2.90 M
|
$1.08 M
|
$565.97 K
|
$1.16 M
|
$427.11 K
|
$389.32 K
|
| Interest Income |
$41.87 K
|
$116.05 K
|
$253.54 K
|
$136.36 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.64 K
|
$13.51 K
|
$38.23 K
|
$22.30 K
|
$15.46 K
|
$8.63 K
|
| Depreciation & Amortization |
$112.12 K
|
$111.64 K
|
$142.26 K
|
$75.27 K
|
$17.88 K
|
$20.44 K
|
$19.90 K
|
$19.32 K
|
$16.78 K
|
$16.02 K
|
| EBITDA |
-$3.14 M |
-$3.04 M |
-$6.01 M |
-$9.41 M |
-$2.90 M |
-$1.25 M |
-$572.47 K |
-$1.07 M |
-$427.11 K |
-$389.32 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$610.21 K
|
$766.32 K
|
$3.96 M
|
$1.98 M
|
$1.25 M
|
-$202.36 K
|
-$63.61 K
|
-$2.71 M
|
-$47.09 K
|
-$25.52 K
|
| Income Before Tax |
-$2.70 M
|
-$3.15 M
|
-$2.20 M
|
-$9.49 M
|
-$1.65 M
|
-$1.28 M
|
-$629.58 K
|
-$3.78 M
|
-$474.20 K
|
-$414.83 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$2.66 M
|
-$3.15 M
|
-$2.86 M
|
-$6.99 M
|
-$1.65 M
|
-$1.28 M
|
-$629.58 K
|
-$3.78 M
|
-$474.20 K
|
-$414.83 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-14.2 |
-27.45 |
-36 |
-118 |
-30 |
-43.25 |
-25.25 |
-150.75 |
-55.75 |
-58 |
| EPS Diluted |
-14.2 |
-27.45 |
-36 |
-118 |
-30 |
-43.25 |
-25.25 |
-150.75 |
-55.75 |
-58 |
| Weighted Average Shares Out |
$189.39 K
|
$115.14 K
|
$79.27 K
|
$59.20 K
|
$43.77 K
|
$29.62 K
|
$25.04 K
|
$25.04 K
|
$8.50 K
|
$7.14 K
|
| Weighted Average Shares Out Diluted |
$189.39 K
|
$115.14 K
|
$79.27 K
|
$59.20 K
|
$43.77 K
|
$29.62 K
|
$25.04 K
|
$25.04 K
|
$8.51 K
|
$7.14 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
